Feeds:
Posts
Comments

Search Results for 'Allergan'


Allergan, Pfizer Deal Goes Through with Allergan Bigger Than Pfizer: But at What Cost to R&D? Curator: Stephen J. Williams, Ph.D. Just recently this site had a post entitled Pfizer Near Allergan Buyout Deal But Will Fed Allow It?  Now, as Bloomberg reports the international deal between Allergan and Pfizer has gone through, resulting in a […]

Read Full Post »


Pfizer Near Allergan Buyout Deal But Will Fed Allow It?     Reporter: Stephen J. Williams, Ph.D. From Bloomberg Business™ Pfizer Inc. is in advanced talks to buy Allergan Plc for as much as $380 per share, according to people familiar with the matter, valuing the Botox maker at as high as $150 billion — […]

Read Full Post »


M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC Reporter: Aviva Lev-Ari, PhD, RN The deal, Allergan Inc.’s $66 billion sale to Actavis PLC, closed on 3/22/2015, ahead of schedule and 11 months after Valeant Pharmaceuticals International Inc. and activist William Ackman’s hedge-fund firm had […]

Read Full Post »


Allergan agrees to $66 billion Actavis offer $219 a share Reporter: Aviva Lev-Ari, PhD, RN   (Reuters) – Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc. Dublin-based Actavis offered $219 per share in cash and stock, amounting […]

Read Full Post »


Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus Dr. Jason Zielonka, MD AFACC Lead Curator – e–mail Contact: Jasonz.mit@gmail.com   Therapeutical options for coronavirus viral infection include the following: (a) Monoclonal and polyclonal antibodies Therapeutic SARS-CoV neutralizing antibodies have been generated and could be retrieved and used again in the event of another SARS-CoV outbreak. Such antibodies would be […]

Read Full Post »


Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings Reporter: Stephen J. Williams, PhD As reported in FiercePharma.com: by Angus Liu | Jun 17, 2019 11:42am Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology. In the first […]

Read Full Post »


From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma   Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes.  It is […]

Read Full Post »


37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 10, 2019: Deals and Announcements Reporter: Stephen J. Williams, Ph.D. From Biospace.com   JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies Published: Jan 10, 2019 By Alex Keown With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing […]

Read Full Post »


37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements Reporter: Stephen J. Williams, Ph.D. From Biospace.com JP Morgan Healthcare Conference Update: FDA, bluebird, Moderna and the Price of Coffee Published: Jan 09, 2019 By Mark Terry at https://www.biospace.com/article/jp-morgan-update-scott-gottlieb-bluebird-bio-eli-lilly-coffee-prices-and-more-by-mark-terry/?s=63   Tuesday, January 8, was another busy day in San Francisco for the JP […]

Read Full Post »


FDA: Rejects NDA filing: “clinical and non-clinical pharmacology sections of the application were not sufficient to complete a review”: Celgene’s Relapsing Multiple Sclerosis Drug – Ozanimod Reporter: Aviva Lev-Ari, PhD, RN   Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis Conference call scheduled for today at 5:30 p.m. ET SUMMIT, N.J.–(BUSINESS WIRE)– Celgene […]

Read Full Post »

Next »